PDCD1 and glioblastoma: Targeting the CLOCK–OLFML3–HIF1α–LGMN–CD162 axis reduces PD-L1 expression and augments anti-PD1 therapy in glioblastoma mice, overall highlighting the therapeutic potential of this pathway (80).